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Introduction
Pancreatic cancer is a devastating disease and is the third leading cause of  cancer-related death in the 
United States (1). Effective therapies are currently lacking, and the 5-year survival rate is less than 10%. 
Activating (oncogenic) mutations in KRAS are present in over 90% of  human pancreatic cancers (2). KRAS 
mutations are present with high frequency in pancreatic intraepithelial neoplasias (PanINs), precursor 
lesions to pancreatic cancer, suggesting an initiating role for mutant KRAS (2, 3). In contrast, mutations 
in tumor suppressor genes such as TP53 and INK4A are absent in low-grade PanINs and rare even in high-
grade PanINs (3, 4). In invasive tumors TP53 mutations are present in up to 75% of  pancreatic cancers (5).
Cancer-associated missense mutations in the TP53 protein have pleiotropic contributions in tumorigen-
esis, including abrogation of  the WT p53 protein’s ability regulate cell cycle checkpoints and apoptosis, and 
bypass oncogene-induced senescence (6). At the same time, these missense-mutant p53 proteins behave as 
gain-of-function mutants (for review, see ref. 7). In fact, different p53 mutant proteins have differing con-
tributions to tumorigenesis in mouse lung cancer models (8). In pancreatic cancer, missense mutations are 
most common, although null alleles are occasionally observed (5, 9).
Pancreatic cancer is characterized by nearly universal activating mutations in KRAS. Among other 
somatic mutations, TP53 is mutated in more than 75% of human pancreatic tumors. Genetically 
engineered mice have proven instrumental in studies of the contribution of individual genes to 
carcinogenesis. Oncogenic Kras mutations occur early during pancreatic carcinogenesis and are 
considered an initiating event. In contrast, mutations in p53 occur later during tumor progression. 
In our model, we recapitulated the order of mutations of the human disease, with p53 mutation 
following expression of oncogenic Kras. Further, using an inducible and reversible expression 
allele for mutant p53, we inactivated its expression at different stages of carcinogenesis. Notably, 
the function of mutant p53 changes at different stages of carcinogenesis. Our work establishes 
a requirement for mutant p53 for the formation and maintenance of pancreatic cancer precursor 
lesions. In tumors, mutant p53 becomes dispensable for growth. However, it maintains the altered 
metabolism that characterizes pancreatic cancer and mediates its malignant potential. Further, 
mutant p53 promotes epithelial-mesenchymal transition (EMT) and cancer cell invasion. This work 
generates new mouse models that mimic human pancreatic cancer and expands our understanding 
of the role of p53 mutation, common in the majority of human malignancies.
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Mice expressing a conditionally activated, oncogenic KrasG12D protein in pancreatic epithelial cells 
(Ptf1a-Cre;LSL-KrasG12D, known as KC mice) develop PanINs — similar to their human counterparts 
— with incomplete penetrance and long latency to malignancy (10). Simultaneous expression of  mutant 
KrasG12D expression and mutant p53R172H — in the model known as KPC — results in the development of  
metastatic pancreatic cancer with high penetrance and a latency of  only a few months (11) as mutant p53 
bypasses oncogene-induced senescence (12). Alternative approaches to the combination of  mutant Kras 
and p53 use inducible Cre systems that allow expression of  the oncogenes in the adult pancreas (13, 14). 
Common to all of  these models is that the mutations in Kras and Tp53 are introduced at the same time. 
Here, we describe a model where we mimic the sequence of  mutations observed in the human disease, by 
introducing the Tp53R270H mutation in PanIN-bearing animals. Further, by using a reversible, doxycycline-
regulated (dox-regulated) expression system, we inactivated p53R270H expression at different stages of  car-
cinogenesis. This system allowed us to investigate the effect of  sequential introduction of  mutations in 
pancreatic cancer, as well as study the role of  mutant p53 at different stages of  carcinogenesis.
Importantly, in our model we have chosen to introduce the Tp53R270H mutation, ortholog to human 
R273H, as position 273 is the most commonly mutated amino acid in pancreatic cancer, as well as in other 
common human tumors, such as colon adenocarcinoma (15).
Results
Mutant p53R270H synergizes with oncogenic Kras to promote pancreatic cancer progression. We classified the spectrum 
of  TP53 mutations in human pancreatic cancer using publicly available data in the Catalogue of  Somatic 
Mutations in Cancer (COSMIC) database (http://cancer.sanger.ac.uk/cosmic). As in many other human 
malignancies, the majority of  TP53 mutations in pancreatic cancer are missense substitutions in the DNA-
binding domain of  the p53 protein (5). The most common Tp53 missense mutation in this data set was 
p53R175H, which corresponds to mouse p53R172H. However, the most frequently mutated codon in pancreatic 
cancer was codon 273. Substitution of  histidine for arginine (R273H) is the most common substitution at 
that position. The corresponding change in the mouse gene is R270H (Figure 1A).
To explore the role of  p53R270H in pancreatic cancer, we designed a construct to express this mutant, as 
well as the fluorescent reporter dsRed, under the control of  a tetracycline-responsive element (TRE). We ini-
tially verified the functionality of  the TREp53R270H cassette in tissue culture. HEK-293 cells were transfected 
with individual plasmids encoding for the reverse tetracycline transactivator (rtTa) and the TREp53R270H con-
struct. Accumulation of  p53 protein was observed by immunoblot in dox-treated cells (Supplemental Figure 
1A; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.97422DS1). 
We then generated transgenic mice carrying the TREp53R270H expression construct. Transgenic TREp53R270H 
animals were crossed with the Krt5-tTa mouse strain, which expresses tTa in the skin, to establish in vivo 
regulation of  the transgene. Expression of  both p53 and dsRed was observed by IHC in the Krt5-tTa; 
TREp53R270H animals and not in control littermates (Supplemental Figure 1B). Therefore, the TREp53R270H 
construct allows for mutant p53 expression in an inducible manner in vitro and in vivo.
To assess the effects of  expressing mutant p53R270H in the context of  mutant Kras pancreata, we gener-
ated Ptf1a-Cre;LSL-KrasG12D;TREp53R270H;R26rtTa/rtTa mice, herein designated as KCip53 mice. The Ptf1a-Cre 
allele expresses Cre recombinase in the pancreatic epithelium, thus leading to expression of  both KrasG12D and 
rtTa. Administration of  dox to the mice induces rtTa-mediated transcriptional activation of  p53R270H. A dsRed 
reporter is expressed at the same time as mutant p53, allowing for a surrogate marker of  dox-inducible gene 
expression (Figure 1B). KCip53 animals were given water or chow containing dox at approximately 4 weeks 
of  age, and the animals were maintained on continuous dox administration. KC littermates were similarly 
kept on dox for the duration of  the experiments, to control for other potential effects of  the antibiotic. Starting 
at 8 months of  age, KCip53 animals developed large pancreatic tumors with metastases to the liver and lung 
(Figure 1C). Accumulation of  p53 protein in the tumors was confirmed by IHC analysis comparing PanIN 
lesions in KCip53 mice with lesions in KC mice (Figure 1D). In KC mouse lesions, p53 protein accumulation 
was occasionally present, as previously observed, likely indicating the accumulation of  p53 in response to 
oncogenic stress induced by KrasG12D (6). In KCip53 compared with KC lesions we observed increased accu-
mulation of  p53, although intriguingly only in a subset of  cells, similar to the Krt5-tTa; TREp53R270H animals 
(Figure 1D and Supplemental Figure 1B). To determine whether the expression of  mutant p53 in this model 
affected tumor progression, we aged the animals until they reached humane endpoints. KCip53 mice had a 
median survival of  275 days, compared to 395 days in KC mice (Figure 1E, n = 94 mice for KCip53, n = 37 
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for KC). Notably, the time to tumor development in KCip53 mice was variable, as was the metastatic load 
and location. Of the animals that were evaluated histopathologically, liver metastases were observed in 8 of  
22 animals and lung metastasis in 6 of  19 (see table in Supplemental Figure 2). Thus, expression of  p53R270H 
accelerated Kras-induced tumorigenesis and led to the development of  metastatic disease.
Figure 1. KCip53 mice recapitulate the stages of human pancreatic cancer. (A) Percentage of human pancreatic tumor samples with p53 R175 or R273 
mutations, from the COSMIC database. (B) Scheme of Ptf1a-Cre;LSLKrasG12D;TREp53R270H;R26rtTa/rtTa animals, termed KCip53 here. (C) H&E from pancreas, 
liver, and lung from two separate KCip53 animals with tumors. (D) IHC for p53 in KC and KCip53 tissue. (E) Survival curve for KC and KCip53 animals. n = 
94 mice for KCip53, n = 37 for KC. Survival significance analysis by log-rank test. All original magnification for histology at ×20, as shown in images. TetO, 
tetracycline operator.
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The TREp53R270H allele in the KCip53 animals is a transgene, and therefore the animals initially retain 
two WT alleles of  Trp53, potentially mitigating some of  the effects of  mutant p53R270H expression. To mimic 
the human scenario, where one allele of  TP53 is mutated and only one WT allele is present, we generated 
animals with the genotype Pdx1-Cre; LSL-KrasG12D; LSL-Trp53R270H, called KPR270HC here (Supplemental 
Figure 3A). In brief, the sequence encoding for p53R270H was inserted in the p53 locus, preceded by a floxed 
stop cassette. Thus, the mutant p53 was expressed upon Cre recombination in the pancreas at the same 
time as mutant Kras, in a model similar to the KPC model (11). KPR270HC mice, similar to KCip53 animals, 
have a shortened life span compared with KC littermates (Supplemental Figure 3B, n = 43 KPR270HC and n 
= 39 KC). Histology from mice at necropsy revealed extensive tumor burden in the KPR270HC animals, with 
metastatic lesions in the liver and lungs (Supplemental Figure 3C). Thus, analysis of  this model corrobo-
rates the phenotype of  the KCip53 mouse.
As an alternative approach, we generated KCip53 animals with one null copy of  p53. The geno-
type of  these mice is Ptf1a-Cre;LSLKrasG12D;TREp53R270H;R26rtTa/rtTa;p53fl/+, and we refer to them herein 
as KCip53;p53fl/+. Given the complexity of  the breeding scheme, we obtained only a relatively small 
cohort of  these mice (n = 18). We observed a trend toward shorter survival in these mice compared 
with KCip53 mice, although the difference was not statistically significant (Supplemental Figure 4A). 
In 4 of  4 KCip53;p53fl/+ mice that were evaluated histopathologically, we did not observe evidence 
of  metastasis (Supplemental Figure 4B). However, these animals had large, locally invasive primary 
tumors (Supplemental Figure 4C). The data thus support the notion that the number of  WT copies of  
p53 present delays the onset of  tumorigenesis.
Mutant p53R270H promotes formation, progression, and maintenance of  PanINs. Given that mice expressing 
mutant p53R270H developed cancer earlier than KC littermates, we sought to determine whether this effect 
was associated with earlier PanIN development. To verify the mechanics of  the KCip53 system, we ana-
lyzed a small cohort of  animals that had never been on dox, and therefore should never have had mutant 
p53R270H expression. KCip53 animals were analyzed at 10 weeks of  age. The resulting histology was similar 
to that of  KC mice, suggesting that, as would be expected, KCip53 animals not on dox did not have expres-
sion of  mutant p53R270H (Supplemental Figure 5, n = 3 KC on dox, n = 4 KCip53 never on dox).
KCip53 and KC littermates were placed on dox at 4 weeks of  age, activating expression of  mutant 
p53R270H protein. At 10 weeks of  age, pancreata were harvested and subjected to histopathological analysis 
(Figure 2A). KCip53 pancreata had more PanINs and less normal tissue than pancreata from KC litter-
mates (Figure 2B and quantification in Figure 2C, n = 3–6 mice per group). In contrast, in a cohort of  
KCip53 mice that were never on dox, PanIN progression was indistinguishable from that of  KC mice, an 
indication that expression of  the mutant p53 protein was tightly regulated (Supplemental Figure 6, n = 3 
KC on dox, n = 4 KCip53 never on dox).
PanIN lesions in KCip53 animals showed characteristic features, including intracellular mucin 
accumulation (as indicated by PAS staining) and elevated pERK, indicating elevated MAPK signaling 
(Figure 2B). Additionally, KCip53 animals had a slight increase in CD45+ immune cells (Supplemental 
Figure 6A) compared with KC controls. STAT3 activation was previously identified as activated down-
stream of  p53R172H in pancreatic cancer cells and a contributing factor in their growth (16). However, 
immunostaining for the active, phosphorylated form of  STAT3 (pSTAT3), revealed no difference in 
expression of  pSTAT3 between KC and KCip53 PanINs, suggesting that a different mechanism might 
be in play during PanIN formation (Supplemental Figure 6B).
Uniquely, the dox-inducible nature of  p53R270H expression allowed us to reverse the expression of  mutant 
p53R270H at different stages of  carcinogenesis. We investigated whether mutant p53R270H expression regulated 
the progression and maintenance of  PanINs. Mice were placed on dox at 4 weeks of  age for 6 weeks. At 
that point, the animals were randomized in cohorts that either stayed on dox or were removed from dox. 
Pancreata from both groups were harvested at 2 days, 1 week, or 3 weeks later (Figure 3A, n = 3–6 mice per 
group). The level of  p53 protein accumulation was assessed by Western blotting of  whole pancreas lysates. 
In KC pancreata, p53 protein was undetectable. In KCip53 mice on dox, we observed p53 accumulation, 
which decreased upon dox removal (Figure 3B). We then compared pancreas histology across the different 
groups. KCip53 mice that were continuously maintained on dox had extensive PanINs and limited acinar 
clusters. In contrast, pancreata from mice that were taken off  dox for 3 weeks after the initial 6-week dosing 
period had limited, low-grade lesions and large areas of  normal acinar clusters (Figure 3C). Within lesions, 
PAS and pERK1/2 staining was present in both on- and off-dox pancreata, but fewer positive lesions were 
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observed in the animals taken off  dox (Figure 3C). These data are consistent with continuous expression of  
mutant p53R270H being required for maintenance of  PanIN lesions and their continued progression.
Given the dramatic differences seen at the 3-week time point after inactivation of  mutant p53, we 
assessed the effects at 1 week or 2 days after removing dox and the associated mutant p53 expression. 
No major histological changes were apparent at these earlier time points (Supplemental Figure 7, n = 
3–6 mice per genotype and time point). We performed qRT-PCR for selected p53-regulated target genes 
in samples from both cohorts over time. Animals that had been off  dox for 1 week had higher levels of  
WT p53–regulated target gene expression, including for Cdkn1a (known commonly, and designated here, 
as p21), Thrombospondin1 (Thbs1) and E-Cadherin (Chd1), compared with KCip53 animals maintained on 
dox (Figure 3D). Acinar markers such as Bhlha15 (known commonly as Mist1) and Elastase were similarly 
upregulated following inactivation of  mutant p53. In contrast, Hes1, which is expressed during acinar de-
differentiation (17), was downregulated (Figure 3E). To determine whether inactivation of  mutant p53 
induced cell death, we evaluated the ratio of  proapoptotic to antiapoptotic factors; our results showed no 
statistically significant differences between the two groups of  animals (data not shown). By IHC, we deter-
mined that E-cadherin, an epithelial marker that is downregulated during carcinogenesis, was higher in 
animals lacking mutant p53 expression (Supplemental Figure 8). Together, our data indicate that during the 
early stages of  carcinogenesis, mutant p53 sustains tumor progression, and are consistent with the notion 
that these animals retain some WT function of  this tumor suppressor.
Expression of  mutant p53R270H is not required to bypass the oncogenic stress induced by activated KrasG12D. We 
next sought to determine whether continued expression of  mutant p53R270H was required for survival 
and growth of  pancreatic cancer cells. As described above, KCip53 mice maintained on dox treatment 
developed invasive, metastatic tumors with variable latency (Figure 1, C and E). The disease burden in 
individual animals is heterogeneous, complicating tumor burden analysis at later ages. To study a cohort 
Figure 2. Mutant p53R270H expression promotes PanIN 
formation. (A) Scheme for mouse treatment for early 
time point analysis. (B) H&E, periodic acid–Schiff 
(PAS), and IHC for pERK in KC and KCip53 animals at 10 
weeks of age. (C) Quantification of pancreatic pathol-
ogy in KC and KCip53 animals, analyzed by 2-way 
ANOVA, presented as mean with SD. n = 3–6 animals 
per genotype. All histology magnification at ×20.
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of  mice carrying genetically identical tumors in which we could modulate mutant p53 expression, we 
established several primary cell lines from cancer-bearing KCip53 mice (Figure 4A). To establish these 
cell lines, we generated single-cell suspensions from the original primary tumors and sorted the cells 
by flow cytometry for expression of  dsRed, as a surrogate marker for cells expressing mutant p53R270H 
Figure 3. Mutant p53R270H expression is required for PanIN maintenance. (A) Scheme for mouse treatment and dox removal. (B) Western blot analysis for 
p53, with each lane representing the lysate from an individual animal. Asterisk indicates a nonspecific band seen in the β-actin blot. (C) H&E, PAS, and IHC 
for pERK in KCip53 animals either on dox or 3 weeks off dox. (D) qRT-PCR analysis of pro- and antiapoptotic factors in KCip53 animals on dox and KCip53 
animals 2 days off dox. (E) qRT-PCR analysis of targets of WT p53 in KCip53 animals on dox and KCip53 animals 1 week off dox. For all qRT-PCR results, 
unpaired t test with Welch’s correction was used, and data are presented as mean with SD. n = 3–6 animals per condition. All histology magnification at ×20.
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(Supplemental Figure 9A). The cell lines were then propagated in culture in the presence of  dox (Figure 
4B). We performed qRT-PCR to study expression of  selected p53-regulated target genes, with the goal of  
determining how changes in expression of  mutant p53 affected p53 transcriptional activity in the cells. 
In cells treated with dox, we saw a reduction in the expression of  the WT p53 target genes Cdkn1a (AKA 
p21) and Thrombospondin1. Conversely, Vimentin, a marker of  epithelial-mesenchymal transition (EMT) 
linked to mutant p53 (18) was downregulated when dox was removed to abrogate p53R270H expression 
(Supplemental Figure 9B, n = 3).
We injected KCip53 cells subcutaneously into immunocompromised (NSG) mice and tracked tumor 
growth over time by caliper measurement. For each cell line, we included 3 conditions: (i) animals never 
given dox (no mutant p53R270H expression; termed “no-dox”); (ii) animals always given dox (continued 
mutant p53R270H expression; “plus-dox”); and (iii) animals started on dox and then removed once tumors 
had become palpable (termed “off-dox”) (Figure 4C, n = 6 or more tumors per group; experiment per-
formed at least twice per cell line). Surprisingly, no differences in tumor growth were observed among these 
3 groups for the KCip53-1 and KCip53-2 cell lines (Figure 4, D and F), and there was no difference in final 
tumor volume or weight among the groups (Figure 4, E and G), indicating that mutant p53R270H expression 
was not required, at least for growth, at late stages of  carcinogenesis.
In human pancreatic cancer samples, mutations in p53 are often accompanied by loss of  heterozygos-
ity and consequent inactivation of  the WT protein (19). To investigate the status of  the WT p53 alleles 
in KCip53 tumor cell lines, we PCR-amplified the region surrounding exons 7 and 8 of  p53 in one KPC 
cell line (20) and two KCip53 cell lines. In the KPC cells, we amplified a 500-bp band consistent with the 
placement of  the primers across an intron (see scheme in Supplemental Figure 10A). In KCip53 cells, we 
Figure 4. Expression of mutant p53R270H 
is not required to bypass the oncogenic 
stress induced by activated KrasG12D. 
(A) H&E of primary tumor from the 
animal from which cell line KCip53-1 was 
generated, shown at ×20 magnification. 
(B) Scheme of cell line generation from 
KCip53 animals. (C) Scheme for subcuta-
neous tumor growth assay. (D) Subcuta-
neous tumor growth curve and (E) final 
tumor volume for KCip53-1 cell line. (F) 
Subcutaneous tumor growth curve and 
(G) final tumor volume for KCip53-2 cell 
line. Data analyzed by 2-way ANOVA, 
no significantly different results in data 
shown in this figure. Data are presented 
as mean with SD. n = 6–8 tumors per 
condition, experiment repeated 2–3 
times for each cell line.
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did not amplify the WT band, but only a shorter band (250 bp), consistent with the cDNA inserted in the 
transgene. Sequencing of  the PCR products confirmed that only the mutant p53 DNA was present on these 
cells, while the WT sequence was lost (Supplemental Figure 10B).
Histological analysis of  the tumors derived from KCip53 cells with or without dox revealed no dif-
ferences in the prevalence of  epithelial cells within the tumors, as measured by expression of  CK19, nor 
in the levels of  proliferation (Ki67) or apoptosis (cleaved caspase-3) (Supplemental Figure 11, A–C). To 
verify the modulation of  Trp53R270H gene expression following dox removal, we performed immunostain-
ing for dsRed. We did not observe any dsRed staining in the tumors from the no-dox cohort. In the plus-
dox cohort, we observed heterogeneous accumulation of  dsRed, similar to our observations in PanINs. 
Fewer dsRed-expressing cells were observed in tumors from the cohort removed from dox (off-dox). Hence, 
dox removal reduced the number of  cells expressing the transgene, although a few cells appeared to have 
escaped regulation and continued to express the transgene in the absence of  dox (Supplemental Figure 
11D). Quantification of  dsRed expression revealed a significantly higher number of  cells per high-power 
field in the dox-treated cohort (Supplemental Figure 11D).
Interestingly, comparison of  the histology of  the tumors from the 3 groups showed differences in epi-
thelial cell morphology. We observed increased muscle invasion in the plus-dox group (Figure 5A, arrows 
indicate muscle invasion). Immunostaining for CK19 highlighted smaller cells with sarcomatoid features 
in the same group (Supplemental Figure 11A). Quantification of  the phenotype revealed muscle invasion 
in 39.3% of  tumors in mice that were never on dox, and 69.7% of  tumors always on dox, suggesting that 
mutant p53R270H expression promotes tumor invasion into the muscle layer (Figure 5B, n = 33 or 34 tumors 
per group). We then measured the expression of  genes associated with EMT, namely Zeb1, Vimentin, and 
Twist1, by qRT-PCR. While the expression of  these genes was generally higher in tumors that maintained 
expression of  mutant p53R270H, the difference was not statistically significant (Figure 5C). Since the inter-
pretation of  the in vivo data is confounded by differences in the microenvironment, we used an in vitro 
system for functional studies. For this purpose, we performed scratch assays using KCip53 cell lines. After 
growing the cells in the presence or absence of  dox, we scratched the plate and monitored time to scratch 
closure. In both KCip53-1 and KCip53-2 lines, cells grown with dox had a shorter time to scratch closure, 
consistent with an increased migration potential (Figure 5D, n = 18 scratch points analyzed per condition). 
In previous studies, the ability of  mutant p53R172H to promote invasion and metastasis of  pancreatic cancer 
cells carrying this specific mutation was mediated by mutant p53–mediated expression of  PDGFRβ (21). 
However, we did not observe any difference in PDGFRβ levels by IHC in subcutaneous tumors grown from 
KCip53-2 cells (Supplemental Figure 12A). Additionally, qRT-PCR for Pdgfrβ in KCip53 pancreata 3 weeks 
off  dox was actually slightly higher than in animals on dox (Supplemental Figure 12B). Together, these data 
indicate that p53R270H may control invasive behavior through a different mechanism than p53R172H.
Given the changes in in vitro migration, and the increased muscle invasion observed in subcutaneous 
models, we implanted KCip53-1 cells orthotopically into the pancreata of  immunocompromised mice 
to determine whether mutant p53R270H expression conferred increased metastatic potential, as previously 
described for p53R172H (12, 21). As in the subcutaneous experiment, we divided the animals into 3 cohorts 
(no-dox, plus-dox, and off-dox). We then measured tumor growth over time by MRI, starting 2 weeks 
after cell implantation and continuing for 3 weeks, when the tumors were harvested (Supplemental Fig-
ure 13A, n = 3–4 animals per group). Similar to the subcutaneous experiment, there was no difference 
in tumor growth rate, final tumor volume, or metastatic spread between the no-dox and plus-dox groups. 
Tumors in the cohort taken off  dox were slightly smaller (Supplemental Figure 13, B–F). Histology of  
the tumors across cohorts was similar. These experiments were performed with only a small group of  
animals, but tumor growth rate and characteristics were consistent with those seen in the subcutaneous 
tumor growth experiments, suggesting that the phenotype is the same. Here mutant p53R270H can confer 
increased migration potential to cells in certain contexts, but its expression is not necessary to alleviate 
the oncogenic stress caused by KrasG12D.
Transcriptional profile of  genes activated downstream of  p53R270H reveals alterations in cellular metabolism. To 
understand the global effects of  expressing p53R270H, we performed RNA sequencing. We subcutaneous-
ly injected KCip53-1 cells into NSG mice and divided the injected mice into 3 experimental groups, as 
described above: no-dox, plus-dox, and off-dox (Figure 6A). We then extracted RNA from bulk, unsorted 
tumors. RNA sequencing analysis revealed marked differences in gene expression profiles among the 3 
treatment groups (n = 4 tumors/group), with the most significant gene expression signature differences 
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Figure 5. Mutant p53R270H expression promotes cell invasion and migration. (A) H&E analysis of final subcutaneous tumors grown from KCip53-1 
cells, shown at ×20 magnification. Arrows indicate some muscle fibers within tumor. (B) Quantification of percentage of final tumors that have 
invasion into muscle by H&E. n = 33 or 34 tumors per group. Analyzed using Fisher’s exact test. (C) qRT-PCR analysis of EMT-associated gene 
expression in final subcutaneous tumors grown from KCip53-1 cells. n = 6–9. For all qRT-PCR results, unpaired t test with Welch’s correction was 
used, and data are presented as mean with SD. (D) Scratch assay in KCip53-1 and KCip53-2 cell lines, shown as percentage original of scratch closed 
at specified time points, analyzed using multiple unpaired t test comparisons, represented as mean with SD. n = 18 scratch points analyzed per 
condition. ****P < 0.0001.
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between the group that had no mutant p53R270H expression and the group of  tumors always expressing 
mutant p53R270H (Figure 6B). Intriguingly, the gene profile established by p53R270H expression did not reverse 
upon inactivation of  the mutant (Figure 6B and Supplemental Table 1).
To analyze the data, we performed pathway analysis and assessed groups of  genes whose expres-
sion changed between the no-dox and plus-dox groups. We also observed changes in cell signaling, cell 
fate, extracellular matrix modeling, and cell motility (Supplemental Figure 14 and Supplemental Table 
2). Mutant p53R270H expression also reduced apoptotic pathways, while conversely upregulating signaling 
pathways that might reflect the increased growth potential of  these cells (growth factor activity, regulation 
of  the ERK1/2 cascade, and regulation of  the insulin receptor signaling pathway). Further, mutant p53R270H 
expression correlated with increased ECM remodeling pathways, cell mobility pathways, and activation 
of  Rho pathway activities that control cytoskeletal dynamics, all linked with cell invasion and migration. 
Among the pathways altered by mutant p53 expression, we identified several that suggested changes in 
metabolism (Figure 6C), including regulation of  the metabolism of  amino acids, carbon sources, fatty 
acids, and autophagy. Given our experimental design, the gene expression differences could reflect changes 
within the tumor cells themselves or in the surrounding stroma in response to epithelial p53 expression.
To functionally investigate whether p53R270H regulates pancreatic ductal adenocarcinoma (PDA) 
metabolism, and determine which specific changes were relevant to the epithelial cell compartment, we 
analyzed intercellular metabolites from primary KCip53 cells with or without dox treatment by targeted 
liquid chromatography–mass spectrometry–based (LC-MS–based) metabolomics (scheme in Supplemen-
tal Figure 15A, n = 3 samples per condition). As the pathway analysis suggested, we observed profound 
changes across the metabolome (Supplemental Figure 15B and Supplemental Table 3). Among these, and 
consistent with the pathway analysis, we found that intracellular branched chain amino acid (BCAA) levels 
were elevated (Figure 6E), which could reflect lower catabolism. BCAAs can be used as a carbon source 
to fuel the tricarboxylic acid (TCA) cycle in the mitochondria. Indeed, we also observed lower levels of  
several metabolites in the TCA cycle (Figure 6F and Supplemental Figure 15C), which could again reflect 
lower mitochondrial activity. Thus, to assess bioenergetic activity directly, we used a Seahorse instrument 
to measure changes in mitochondrial metabolism and glycolysis, as read out by oxygen consumption rate 
(OCR) and extracellular acidification (ECAR), respectively. This was performed for primary KCip53 cell 
lines and a primary cell line isolated from a mouse Pdx-Cre;KrasLSL-G12D;p53R172H (KPC) tumor. The latter 
do not depend on dox for their mutant p53 expression and served as controls. We observed a decrease in 
OCR in the KCip53 cell lines, but not in the KPC line, upon dox treatment (Figure 6D and Supplemental 
Figure 16A, n = 5 samples per condition). Changes in p53 levels in KCip53 cell lines upon dox treatment, 
but not KPC were confirmed by Western blot analysis (Supplemental Figure 16B). These functional data 
provide direct evidence that mutant p53R270H expression reduces mitochondrial activity, which may result 
from decreased BCAA metabolism.
Inactivation of  mutant p53R270H function sensitizes tumors to MEK inhibition. Upward of 90% of pancreatic can-
cers harbor oncogenic Kras mutations, but no targeting agents are currently available (for review, see ref. 22). 
Attempts to target downstream effector pathways activated by oncogenic Kras, such as PI3K/AKT or MAPK 
signaling (22) — both important in pancreatic carcinogenesis (23–27) — have similarly been unsuccessful (28). 
To determine whether inactivation of Trp53R270H expression, and subsequent reactivation of WT p53, sensitized 
pancreatic cancer cells to MAPK or AKT inhibition, we designed a set of experiments. We injected NSG 
mice subcutaneously with KCip53-1 cells. Initially, all the mice were kept on dox to express mutant p53. In 
our first experiment, we tested for MEK sensitivity. Once the tumors were palpable (approximately 2 weeks 
after injection), we subdivided the mice into 4 groups: (i) on dox with vehicle; (ii) on dox with MEK inhibi-
tor (PD325901, 5 mg/kg administered daily by oral gavage); (iii) off  dox with vehicle; and (iv) off  dox with 
MEK inhibitor (Figure 7A, n = 5 mice per group, two tumors implanted per mouse). We measured tumor vol-
ume over time by MRI. Similar to previous observations (20, 23), MEK inhibition slowed but did not reverse 
tumor growth, whether or not mutant Trp53R270H was expressed. Abrogation of mutant p53 expression slightly 
decreased tumor growth, while MEK inhibition cooperated with abrogation of mutant p53R270H to decrease 
tumor growth (Figure 7B). By immunostaining and Western blot analysis, we observed decreased phospho-
ERK1/2 (indicating MAPK activity) in the MEK inhibitor–treated samples and increased expression of dsRed 
(as readout for mutant p53 expression) in samples from mice on dox both with and without drug treatment, 
as expected (Supplemental Figure 17). We did not observe changes in proliferation (measured by Ki67) or 
apoptosis (by cleaved caspase-3 staining) in any of the groups, possibly due to the fact that histological analysis 
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Figure 6. Transcriptional profile of genes activated downstream of p53R270H reveals alterations in cellular metabolism. (A) Scheme for subcutaneous 
tumor growth and RNA collection for RNA-seq. n = 4 samples per group. (B) Heatmap showing differential gene expression in tumor groups. (C) Path-
way analysis of gene expression differences in no-dox and plus-dox conditions. (D) Change in OCR levels as measured by mitochondrial stress test in 
KPC, KCip53-1, and KCip53-2 cells with or without dox, analyzed using 1-way ANOVA. n = 5 replicates per condition. Difference of levels of (E) branched 
chain amino acids and (F) TCA intermediates in KCip53-1 cells grown with or without dox, analyzed using unpaired t test with Welch’s correction, shown 
as mean with SD. n = 3 samples per group.
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was performed long after the start of drug treatment. The MEK-inhibited and off-dox group displayed higher 
levels of fibrosis, reflecting the slowing of cell growth in these tumors (Supplemental Figure 17). Histological 
characterization of the tumors showed changes in cellular architecture, with more ductal structures and a less-
sarcomatoid appearance in the tumors from MEK-inhibited groups (Figure 7C). We, and others, have previ-
ously shown that MEK signaling regulates epithelial growth and differentiation as well as aspects of stroma 
activation and remodeling (23, 24, 26, 29). Thus, the changes in the accumulation of the stroma and tissue 
architecture might reflect a combination of cell-autonomous and non-cell-autonomous effects.
Following the MEK inhibition studies, we pursued efforts to study combined inhibition of  MEK and 
PI3K, an upstream regulator of  AKT, in mice harboring the KCip53 tumors. We injected NSG mice subcu-
taneously with KCip53-1 cells, and animals remained on dox, with mutant p53R270H expression, throughout 
the experiment. Once the tumors were palpable, we started drug treatment in all 4 groups: vehicle, MEK 
inhibition, PI3K inhibition, and dual MEK and PI3K inhibition (Figure 7D, n = 4 animals per group, 
two tumors implanted per animal). The MEK inhibitor PD325901 was administered orally, once daily 
at a dose of  5 mg/kg. The PI3K inhibitor ZSTK-474 was administered orally once daily at a dose of  100 
mg/kg. Tumor growth was assessed using MRI for exact volume measurements. As expected, tumors in 
the control group grew the fastest, while single MEK or PI3K inhibition had a modest inhibitory effect 
on growth, which was statistically significant only for PI3K inhibition. The combination of  MEK and 
PI3K inhibition potently inhibited tumor growth, with no increase in tumor volume seen in 4 of  8 tumors, 
although no regression of  tumors was evident (Figure 7E). We confirmed MEK and PI3K inhibition in 
the respective treatment groups by Western blot analysis, observing downregulation of  pERK1/2 in the 
MEK inhibitor–treated groups and reduced pAKT in the PI3K inhibitor groups (Supplemental Figure 18). 
Interestingly, while vehicle-treated tumors showed sarcomatoid histology, consistent with the histology of  
this cell line, inhibition of  either MEK or PI3K led to an increase in ductal structures surrounded by fibrotic 
stroma (Figure 7F). In the dual MEK/PI3K inhibitor–treated samples we observed ductal structures sur-
rounded by stroma with lower cellularity than any of  the other groups. Proliferation, measured as Ki67-
positive nuclei, was lowest in the dual inhibitor–treated tumors. In contrast, we did not observe changes 
in apoptosis (cleaved caspase-3 expression) in any of  the groups, although it is possible that we missed an 
earlier wave of  cell death (Supplemental Figure 18). Thus, restoration of  WT p53 function at least partially 
sensitized pancreatic tumor cells to MEK inhibition; however, expression of  the specific Trp53R270H mutant 
did not change response to combined MEK and PI3K inhibition, compared with other pancreatic cancer 
cell lines. These novel KCip53 cell lines constitute a platform for testing the effects of  WT p53 restoration 
in combination with targeted inhibitors.
Discussion
In human tumors, the majority of TP53 mutations in pancreatic cancer lead to the expression of a missense 
mutant p53 protein that can still oligomerize with WT p53 but fails to function as a sequence-specific DNA 
transcription factor (4, 5, 30). Consistent with the human data, expression of mutant Kras in the pancreas is 
sufficient to initiate carcinogenesis, while Trp53 mutations have little effect on their own but promote carci-
nogenesis in the presence of oncogenic Kras (10, 11). Of the spectrum of human mutations, two types have 
been studied in mouse models: p53 deletion and a substitution of histidine for arginine at codon 172 of the 
mouse protein (p53R172H), ortholog to R175H in the human p53 protein. Deletion of one or both alleles of  
p53, in the presence of oncogenic Kras, leads to invasive pancreatic tumors with short latency and high pen-
etrance (31). In the commonly used KPC model, p53R172H is expressed alongside oncogenic Kras; this model 
has slightly longer latency to invasive disease and, at least in some reports, increased metastatic potential (11). 
However, these models introduce both Kras and p53 mutations at embryonic stages, and do not mimic the 
sequence of mutations that occur in human tumors. In this study, we reanalyzed a public sequencing database 
(COSMIC) to determine the prevalence of individual TP53 mutations in human pancreatic cancer. The codon 
encoding for amino acid 273 of the human protein was the most frequent mutation site; at this site, the most 
common mutation was R273H. Interestingly, this mutation is considered a p53 “hotspot” mutation, and is 
one of the most common mutations in human tumors of all types (32). Since this specific mutation had not 
been expressed in the pancreas in mice expressing mutant Kras, we set out to model it. Thus, we expressed 
Trp53R270H, the mouse ortholog to human TP53R273H, in the KC mouse model of pancreatic cancer. The KCip53 
mouse combines expression of oncogenic Kras with Trp53R270H, and it is designed to have two unique features: 
(i) Trp53R270H expression in this model is inducible, thus allowing sequential activation of mutant genes; and (ii) 
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Trp53R270H expression is reversible, and thus inactivation of its expression and, consequently, restoration of WT 
function — at least until loss of heterozygosity (LOH) for p53 occurs spontaneously — can be regulated at will. 
Similar to p53R172H, p53R270H synergizes with oncogenic Kras to promote pancreatic carcinogenesis. However, 
a comparison between KPC mice, expressing p53R172H, and the KCip53 model revealed slower progression to 
Figure 7. Inactivation of mutant p53R270H function sensitizes tumors to MEK inhibition. (A) Scheme for subcutaneous tumor growth and drug treat-
ment using KCip53-1 cells in MEK inhibition and p53R270H on and off groups. (B) Subcutaneous tumor growth curve for treatment groups using KCip53-1 
cells. MEKi, MEK inhibition. (C) H&E analysis of final tumors. (D) Scheme for subcutaneous tumor growth and drug treatment using KCip53-1 cells 
in MEK inhibition and AKT inhibition groups. (E) Subcutaneous tumor growth curve for treatment groups using KCip53-1 cells. (F) H&E analysis of 
final tumors. n = 10 tumors per group for MEK inhibition, n = 8 tumors per group for MEK and PI3K inhibition. Histology shown at ×20 magnification. 
Tumor growth analyzed by 2-way ANOVA, shown as mean with SD.
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malignancy in the latter. Different explanations are possible for this finding, including the later time of activa-
tion of mutant p53 (in adult mice rather than in embryogenesis), as well as the fact that the KCip53 model 
retains two copies of the WT allele. Interestingly, KCip53 mice develop a highly metastatic tumor, which is 
consistent with a role for p53 in inducing EMT, one of the mechanisms of metastatic disease spread. Further, 
tumors expressing mutant p53 showed increased intramuscular invasion in the subcutaneous setting, reflecting 
our observation in vitro, where mutant p53 promotes cellular migration.
A unique feature of  the KCip53 model is the reversible nature of  mutant p53 expression, which allows 
us to restore WT p53 function at will, as well as to understand mutant-specific phenotypes. In PanIN 
lesions, expression of  the mutant was continuously required for progression, and inactivation of  mutant 
p53 led to an increase in expression of  WT p53 target genes, such as p21, that inhibit growth. The mutant 
protein also facilitated survival of  epithelial cells exposed to Kras-driven oncogenic stress, and its inac-
tivation increased the ratio of  proapoptotic to antiapoptotic factors. Our data support a model whereby 
PanIN progression to cancer is unlikely if  WT p53 is retained, as is the case in the majority of  human 
PanINs (3). Conversely, acquisition of  mutations in the Trp53 gene allows bypassing this early arrest and 
progression to cancer. Unique to our model, inactivation of  mutant p53 inhibits progression even once the 
neoplastic process has begun. Similar to our findings, restoration of  WT p53 in liver and lung tumors limits 
cancer progression by inducing apoptosis (33–35). In those studies, WT p53 expression was restored to 
autochthonous tumors that had developed in the absence of  p53 expression in mutant Ras-driven liver or 
lung tumor models. In each of  these models, WT p53 restoration led to tumor regression. For this reason, 
restoration of  WT p53 function has been hypothesized as a potential therapeutic approach — an attractive 
prospect given that p53 is lost or mutated in the vast majority of  human malignancies (32). Each of  the p53 
restoration studies relied on models that had lost p53 function. Given that p53 mutation, instead of  loss of  
function, is common in human cancer development, the KCip53 animals provide a unique system to test 
questions of  WT p53 restoration in tumor therapy.
Our PanIN studies supported the idea that restoration of  WT p53 protein limits tumor progression. Sur-
prisingly, in invasive tumors, mutant p53R270H inactivation had no apparent effect on tumor growth, at least in 
the transplantation setting, indicating that other mechanisms might compensate to avoid oncogene-induced 
senescence. Sequencing analysis revealed that the tumor cells had lost their WT copies of  p53, possibly 
explaining their continued growth even upon inactivation of  the mutant protein. Nevertheless, other funda-
mental tumor characteristics depended on continuous expression of  the mutant p53R270H protein. RNA-seq 
analysis revealed profound changes induced by mutant p53 expression. However, inactivation of  p53R270H 
in established tumors failed to restore the baseline gene expression pattern. In other words, expression of  
mutant p53 altered the transcriptome of  the tumor cells, but its removal failed to restore transcription to the 
baseline pattern. This finding might explain the lack of  dependence on mutant p53 of  the KCip53 cell lines, 
although selective pressure to retain transgene expression might play a role as well. Pathway analysis illumi-
nated many processes that are perturbed by expression of  mutant p53R270H, several of  which have been previ-
ously identified as important in pancreatic cancer. Among these, we found changes in the MAPK and Rho 
family signaling pathways, both critical for pancreatic tumorigenesis (26, 36–38). Mutant p53R172H expression 
in pancreatic cancer cells induces metastasis, an effect that was attributed to activation of  PDGFRβ (21). 
Analysis of  the RNA-seq data revealed induction of  Pdgfrβ upon expression of  p53R270H, albeit to a modest 
extent. IHC staining for PDGFRβ expression in subcutaneous tumor tissue revealed high levels of  PDGFRβ 
expression even in no-dox tumors, which may explain the only modest increase in the plus-dox condition.
Conversely, cellular metabolism was profoundly altered by expression of  mutant p53R270H. The complex 
role of  p53 in the regulation of  cellular metabolism is an area of  active investigation, and it is increasingly 
being understood that p53 directly influences multiple metabolic pathways (39). An interesting observa-
tion, based on pancreatic cancer patient–derived xenografts, is that lack of  p53 function sensitizes tumors 
to inhibition of  lactate dehydrogenase (40), indicating a link between p53 function and glycolysis in pan-
creatic cancer. It has also been suggested that p53 function can play a role in the regulation of  autophagy 
in pancreatic tumorigenesis, (41, 42). Here, using gene expression profiles, we identified that the glycolysis 
and autophagy pathways are altered as a result of  p53R270H expression. These results, coupled with the 
observed decrease in mitochondrial activity when mutant p53R270H is expressed, suggest that p53 mutations 
play an integral role in the metabolic wiring of  pancreatic cancer cells. Supporting this notion, changes in 
metabolic phenotype in pancreatic cancer change when the cells undergo EMT (43). The potential causal 
relationship between EMT and metabolic changes induced by mutant p53 remains to be elucidated.
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Interestingly, pathway analysis of  our RNA-seq data revealed downregulation of  BCAA metabolism 
upon expression of  p53R270H. Further, we confirmed this finding by measuring metabolite abundance. The 
incorporation of  BCAA-derived carbon into the TCA cycle decreases in pancreatic tumors harboring a 
Kras mutation and p53 LOH, relative to corresponding normal pancreas (44). Similarly, we observed that 
the BCAA degradation pathway was downregulated upon expression of  p53R270H, indicating that in this 
context p53 mutation acts similarly to p53 loss. Taken together, these observations suggest a key role for 
mutant p53 in shaping the nutrient acquisition of  pancreatic cancer cells. Thus, future research into the 
mechanisms by which p53 mutations shape PDA metabolism might identify potential sensitivities of  p53 
mutant tumors suitable for therapeutic targeting.
We, and others, have previously shown that pancreatic cancer requires continuous oncogenic Kras 
activity (45–47). We have also identified several therapeutically actionable mechanisms by which Kras 
drives the re-wiring of  pancreatic cancer metabolism (47, 48). The data presented here represent an initial 
snapshot into the metabolic landscape of  pancreatic cancer as shaped by mutations in the tumor suppressor 
p53, which may serve to highlight new therapeutic vulnerabilities. While our model uses genetic manipu-
lation to inactivate mutant p53R270H expression in pancreatic cancer, a new generation of  conformational 
drugs has been developed for this purpose (33, 49–53). Our results indicate that those drugs by themselves 
might have limited effect on pancreatic cancer growth. However, combined targeting of  mutant p53 and 
specific metabolic pathway inhibitions might reveal unexpected vulnerabilities of  pancreatic cancer. Identi-
fication of  ideal combinations and of  the appropriate patient population — among the different pancreatic 
cancer subsets (9, 19, 54–56) — will be essential to move this concept toward the clinic.
Methods
Mice. Mice were housed in specific pathogen–free facilities at the University of  Michigan Comprehensive 
Cancer Center. This study was approved by the University of  Michigan Committee on Use and Care 
of  Animals (UCUCA). Ptf1a-Cre, Pdx1-Cre, LSL-KrasG12D, LSL-Tp53R270H, and R26-rtTa animals have 
been previously described (10, 11, 45, 57), and TREp53R270H animals were generated at the University of  
Michigan (E.R. Fearon). Animals were analyzed at various ages, as described in the text. KCip53 animals 
were not backcrossed and were maintained on a mixed background. Dox was administered in the drink-
ing water (0.2 g/l in a 5% sucrose solution) or chow (1 g/kg) and replaced every 3–4 days. Immunocom-
promised (NSG) animals were used for all subcutaneous or orthotopic tumor growth experiments. NSG 
animals of  both sexes were ordered from the Jackson Laboratory. Animals were ordered at 6–8 weeks of  
age, and experiments were initiated within a week of  the arrival of  mice at the University of  Michigan. 
For subcutaneous tumors, 500,000 cells were injected in a 200-μl solution of  50% Matrigel and 50% RPMI 
media. Each mouse was implanted subcutaneously with two tumors, and tumor growth was recorded at 
least 3 times weekly until tumors reached a 1.5-cm diameter. For orthotopic tumors, mice were anesthe-
tized using vaporized isoflurane. 500,000 cells were injected into a 50-μl solution of  50% Matrigel and 
50% RPMI media directly into the pancreas. The incision was closed using absorbable sutures and clips. 
Postsurgical animals were monitored daily for 10 days, and then at least 3 times weekly for the duration of  
the experiment. For drug treatments, animals were treated with PD325901 at a dose of  5 mg/kg, ZSTK-
474 at a dose of  100 mg/kg, or vehicle. Combination treatment was given using the same doses for single 
drug treatment. All treatments were given by oral gavage once daily.
IHC. Histology and IHC studies were performed as previously described (45). Primary antibodies used 
are detailed in the supplemental material.
qRT-PCR. RNA isolation, RT-PCR, and qRT-PCR were performed as previously described (45). 
Cyclophilin A was used as the control housekeeping gene for normalization. Primers used are listed in the 
supplemental material.
Histopathological analysis. Histopathological analysis was performed using H&E-stained sections, with 
the pathologist being blinded to each animal’s genotype. At least 3 independent animals were analyzed 
from each group, with a minimum of  50 acinar or ductal clusters being counted from each animal. Five 
representative, non-overlapping, high-power images were analyzed from each slide, with one slide being 
analyzed per animal. Each cluster was classified as acinar or PanIN1A, -1B, -2, or -3, based on the clas-
sification consensus.
Western blot analysis. Protein isolation and Western blot analysis were performed as previously described 
(45). Antibodies used are detailed in the supplemental materials.
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Cell culture. KCip53 cell lines were derived from mice of  the genotype Ptf1a-Cre;LSL-
KrasG12D;TREp53R270H;R26rtTa/rtTa. Pancreata or tumors from these animals were minced with scissors and 
digested in 1 mg/ml collagenase. Tumor cells were then sorted from these cultures using FACS, sorting for 
the expression of  dsRed. All cells were cultured in RPMI supplemented with 10% FBS and 1% penicillin/
streptomycin (Gibco). Dox was administered to cells at a concentration of  2 μg/ml.
Scratch assay. Cells were plated in a 6-well plate and grown until confluent. Scratches were created with 
a pipette tip. Scratches were then measured in the same location at each time point. Distance of  scratch 
closure was measured using ImageJ (NIH).
MRI. Mice were anesthetized with 1%–2% isoflurane/air, and body temperature was maintained using 
a Multistation Temperature Control Unit (Minerve Equipment Veterinaire.) MRI scanning was performed 
using a 3T translational, cryogen-free, preclinical MRI (MR Solutions; MRS 3000 series) with a quadra-
ture mouse body volume coil. Mice were placed supine in the mouse bed. To reduce respiratory motion, 
surgical tape was used to secure the mice below the thoracic cavity on the bed. T2-weighted images were 
acquired using a fast spin echo multi-slice sequence with the following parameters: repetition time (TR)/
echo time (TE) = 4,500/34 ms, 8 echo trains, 4 averages, field of  view (FOV) = 35 × 35 mm2, matrix size = 
128 × 128, slice thickness = 2 mm, number of  slices = 30, and no gap. Using in-house software, the tumor 
boundary was manually defined on each slice and then integrated across slices to measure the volume.
RNA-seq. Tissue from subcutaneous tumors was collected in lysis buffer for RNA extraction. RNA was 
isolated using the QIAGEN AllPrep DNA/RNA/miRNA Universal Kit according to the manufacturer’s 
instructions. PolyA+, non-strand-specific libraries were prepared by the University of  Michigan Sequenc-
ing Core, and all samples were sequenced on an Illumina HiSeq 4000. RNA-seq data are available at the 
NCBI’s Gene Expression Omnibus database (GEO GSE106853).
RNA-seq data analysis. 50-bp, single-end reads were mapped to the mouse reference genome (mm9) using 
TopHat v 1.4.1 (58). The NCBI RefSeq transcript isoform annotation was condensed to an unstranded, 
gene-level annotation and quantification performed over unambiguous exonic spans per gene. Gene expres-
sion was calculated as RPKM (reads per kilobase million; using exonic, base-wise coverage, normalized by 
summed lengths of  exons and total mapped read count). Differential gene expression was performed using 
DE2 v1.12.4 (59). Differentially expressed genes were defined as being expressed more than 0.25 RPKM 
(mean value across all samples in a given comparison), greater than 250 bp in length, changing more than 
1.5-fold, and having an adjusted P value from DESeq2 of  less than 0.1. For cluster analysis and heatmap 
generation, gene expression values were log10 transformed and z-score standardized across samples. Hier-
archical clustering was performed using Euclidean distance and complete linkage. RNA-seq data are avail-
able at the NCBI’s GEO database (GSE106853).
Metabolic flux assay. To estimate the rate of  glycolysis and mitochondrial respiration, a Seahorse Meta-
bolic Flux Analyzer e96 XF instrument (Agilent) was used according to the manufacturer’s manual. 20,000 
cells/well of  KPC, KCip53-1, or KCip53-2 cells were seeded in the respective culture media the day prior 
to the assay. The next day media was exchanged to the Seahorse assay media, containing 25 mM glucose, 
adjusted to 7.4 pH. The cell plate was allowed to equilibrate for 1 hour in a non-CO2, 37°C incubator, and 
following 3 sequential measurements for the basal respiration, a Seahorse XF Mito Stress assay (Agilent) 
was performed by injections of  1 μM oligomycin, 1 μM FCCP, 0.5 μM rotenone/0.5 μM antimycin A. 
All the chemicals were obtained from Sigma-Aldrich. The cell number adjustment was performed using 
CyQuant NF (Thermo) after the assay. The data are presented as mean and SD.
Label-free targeted metabolomics and data analysis. PDA cells were plated in triplicate and treated with dox 
containing medium or normal RPMI with 5% FBS for 3 days. The medium was removed and the cell lysate 
harvested with ice-cold 80% MeOH. The soluble metabolite fractions were cleared by centrifugation, dried 
via SpeedVac (Thermo Fisher), then resuspended in a 50:50 MeOH/H2O mixture for LC–MS analysis. We 
performed label-free targeted metabolomics using in-house LC-MS to measure more than 200 metabolites. 
The bioinformatic data analysis was done using R/Bioconductor (http://www.bioconductor.org). Further 
details are provided in the supplemental methods.
Statistics. All data is represented as mean with SD. For analysis of  qRT-PCR, unpaired t test with 
Welch’s correction was used. Subcutaneous tumor growth experiments were analyzed by 2-way ANOVA. 
A P value of  less than 0.05 was considered significant for all analyses. Statistical analysis was performed in 
GraphPad Prism software.
Study approval. All animal studies were approved by the University of  Michigan UCUCA.
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